Last reviewed · How we verify
MultiTAA-specific T cells
MultiTAA-specific T cells is a Biologic drug developed by Baylor College of Medicine. It is currently in Phase 1 development. Also known as: Multiple tumor-associated antigen (TAA)-specific T cells.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MultiTAA-specific T cells |
|---|---|
| Also known as | Multiple tumor-associated antigen (TAA)-specific T cells |
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant (PHASE2)
- TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (PHASE1, PHASE2)
- Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (PHASE1)
- Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (PHASE1)
- Administration of Donor MultiTAA-Specific T Cells for ALL (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MultiTAA-specific T cells CI brief — competitive landscape report
- MultiTAA-specific T cells updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI
Frequently asked questions about MultiTAA-specific T cells
What is MultiTAA-specific T cells?
Who makes MultiTAA-specific T cells?
Is MultiTAA-specific T cells also known as anything else?
What development phase is MultiTAA-specific T cells in?
Related
- Manufacturer: Baylor College of Medicine — full pipeline
- Also known as: Multiple tumor-associated antigen (TAA)-specific T cells
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing